Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma.

Fridrik MA, Hausmaninger H, Lang A, Drach J, Krieger O, Geissler D, Michlmayr G, Ulsperger E, Chott A, Oberaigner W, Greil R.

Ann Hematol. 2010 Mar;89(3):273-82. doi: 10.1007/s00277-009-0811-x. Epub 2009 Aug 20.

PMID:
19693500
2.

Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.

Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert M, Denison U, Mlineritsch B, Steger G, Kwasny W, Stöger H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Pötter R, Gnant M; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2008 Apr 1;14(7):2082-7. doi: 10.1158/1078-0432.CCR-07-2068.

3.

Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.

Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, Menzel C, Piswanger-Soelkner JC, Galid A, Mittlboeck M, Hausmaninger H, Jakesz R; Austrian Breast and Colorectal Cancer Study Group.

J Clin Oncol. 2007 Mar 1;25(7):820-8. Epub 2006 Dec 11.

PMID:
17159195
4.

Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study.

Marth C, Windbichler GH, Hausmaninger H, Petru E, Estermann K, Pelzer A, Mueller-Holzner E.

Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1522-8.

PMID:
16884360
5.

A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer.

Schippinger W, Jagoditsch M, Sorré C, Gnant M, Steger G, Hausmaninger H, Mlineritsch B, Schaberl-Moser R, Mischinger HJ, Hofbauer F, Holzberger P, Mittlböck M, Jakesz R; Austrian Breast and Colorectal Cancer Study Group.

Br J Cancer. 2005 May 9;92(9):1655-62.

6.

Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR).

Nachbaur D, Greinix HT, Koller E, Krieger O, Linkesch W, Kasparu H, Pober M, Hinterberger W, Hausmaninger H, Heistinger M, Ulsperger E, Karlhuber S, Schwinger W, Lindner B.

Ann Hematol. 2005 Jul;84(7):462-73. Epub 2005 Feb 23.

PMID:
15726362
7.

Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group.

Filipits M, Pohl G, Rudas M, Dietze O, Lax S, Grill R, Pirker R, Zielinski CC, Hausmaninger H, Kubista E, Samonigg H, Jakesz R.

J Clin Oncol. 2005 Feb 20;23(6):1161-8.

PMID:
15718312
8.

Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial.

Schmid P, Schippinger W, Nitsch T, Huebner G, Heilmann V, Schultze W, Hausmaninger H, Wischnewsky M, Possinger K.

J Clin Oncol. 2005 Jan 20;23(3):432-40.

PMID:
15659490
9.

Phase II study of single-agent pegylated liposomal doxorubicin HCl (PLD) in metastatic breast cancer after first-line treatment failure.

Mlineritsch B, Mayer P, Rass C, Reiter E, Russ G, Vesenmayer G, Oberaigner W, Hausmaninger H.

Onkologie. 2004 Oct;27(5):441-6.

PMID:
15585973
10.

Long-term results of dose density therapy in patients with aggressive lymphoma.

Fridrik MA, Hausmaninger H, Linkesch W, Greil R, Krieger O, Baldinger C, Klocker J, Pont J, Oberaigner W.

Ann Hematol. 2005 Apr;84(4):217-22. Epub 2004 Nov 6.

PMID:
15538568
11.

Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer: a phase II study.

Hausmaninger H, Morack G, Heinrich B, Wallwiener D, Höffken K, Buksmaui S, Krejcy K, Miller MA, Possinger K.

Am J Clin Oncol. 2004 Aug;27(4):429-35.

PMID:
15289740
12.

Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer.

Schoppmann SF, Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M, Kubista E, Hausmaninger H, Samonigg H, Gnant M, Jakesz R, Horvat R; Austrian Breast and Colorectal Cancer Study Group.

Ann Surg. 2004 Aug;240(2):306-12.

13.

High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin.

Pohl G, Rudas M, Dietze O, Lax S, Markis E, Pirker R, Zielinski CC, Hausmaninger H, Kubista E, Samonigg H, Jakesz R, Filipits M.

J Clin Oncol. 2003 Oct 1;21(19):3594-600.

PMID:
14512390
14.

Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients.

Ploner F, Jakesz R, Hausmaninger H, Kolb R, Stierer M, Fridrik M, Steindorfer P, Gnant M, Haider K, Mlineritsch B, Tschurtschenthaler G, Steger G, Seifert M, Kubista E, Samonigg H; Austrian Breast And Colorectal Cancer Study Group.

Onkologie. 2003 Apr;26(2):115-9.

PMID:
12771518
15.

Significant increase in breast conservation in 16 years of trials conducted by the Austrian Breast & Colorectal Cancer Study Group.

Jakesz R, Samonigg H, Gnant M, Kubista E, Depisch D, Kolb R, Mlineritsch B, Mischinger HJ, Menzel RC, Steindorfer P, Kwasny W, Tausch C, Stierer M, Taucher S, Seifert M, Hausmaninger H; Austrian Breast & Colorectal Cancer Study Group.

Ann Surg. 2003 Apr;237(4):556-64.

16.

Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.

Schmid M, Jakesz R, Samonigg H, Kubista E, Gnant M, Menzel C, Seifert M, Haider K, Taucher S, Mlineritsch B, Steindorfer P, Kwasny W, Stierer M, Tausch C, Fridrik M, Wette V, Steger G, Hausmaninger H.

J Clin Oncol. 2003 Mar 15;21(6):984-90.

PMID:
12637461
17.

A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).

Kühr T, Burgstaller S, Apfelbeck U, Linkesch W, Seewann H, Fridrik M, Michlmayr G, Krieger O, Lutz D, Lin W, Pont J, Köck L, Abbrederis K, Baldinger C, Buder R, Geissler D, Hausmaninger H, Lang A, Zabernigg A, Duba C, Hilbe W, Eisterer W, Fiegl M, Greil R, Gastl G, Thaler J; Austrian CML Study Group.

Leuk Res. 2003 May;27(5):405-11.

PMID:
12620292
18.

A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer.

Paridaens R, Van Aelst F, Georgoulias V, Samonnig H, Cocquyt V, Zielinski C, Hausmaninger H, Willemse P, Boudraa Y, Wildiers J, Ramazeilles C, Azli N.

Ann Oncol. 2003 Mar;14(3):433-40.

PMID:
12598350
19.

Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5.

Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C, Bauernhofer T, Seifert M, Haider K, Mlineritsch B, Steindorfer P, Kwasny W, Fridrik M, Steger G, Wette V, Samonigg H; Austrian Breast and Colorectal Cancer Study Group Trial 5.

J Clin Oncol. 2002 Dec 15;20(24):4621-7.

PMID:
12488405
20.

Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer.

Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2002 Jun;8(6):1831-7.

21.

Chemotherapy versus hormonal adjuvant treatment in premenopausal patients with breast cancer.

Jakesz R, Hausmaninger H, Samonigg H.

Eur J Cancer. 2002 Feb;38(3):327-32. Review.

PMID:
11818196
22.

Prognostic relevance of three histological grading methods in breast cancer.

Latinovic L, Heinze G, Birner P, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Gnant M, Jakesz R, Oberhuber G; Austrian Breast and Colorectal Cancer Study Group.

Int J Oncol. 2001 Dec;19(6):1271-7.

PMID:
11713599
23.

Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer.

Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Kandioler-Eckersberger D, Gnant M, Jakesz R; Austrian Breast & Colorectal Cancer Study Group.

Clin Cancer Res. 2001 Jun;7(6):1669-75.

24.

Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial.

Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J, Denison U, Müller-Holzner E, Marth C.

Br J Cancer. 2000 Mar;82(6):1138-44.

25.

Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.

Jakesz R, Hausmaninger H, Haider K, Kubista E, Samonigg H, Gnant M, Manfreda D, Tschurtschenthaler G, Kolb R, Stierer M, Fridrik M, Mlineritsch B, Steindorfer P, Mittlböck M, Steger G.

J Clin Oncol. 1999 Jun;17(6):1701-9.

PMID:
10561206
26.

Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian Breast Cancer Study Group.

Kucera E, Speiser P, Gnant M, Szabo L, Samonigg H, Hausmaninger H, Mittlböck M, Fridrik M, Seifert M, Kubista E, Reiner A, Zeillinger R, Jakesz R.

Eur J Cancer. 1999 Mar;35(3):398-405.

PMID:
10448289
27.

Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study.

Hausmaninger H, Moser R, Samonigg H, Mlineritsch B, Schmidt H, Pecherstorfer M, Fridrik M, Kopf C, Nitsche D, Kaider A, Ludwig H.

Eur J Cancer. 1999 Mar;35(3):380-5.

PMID:
10448286
28.

[Therapy studies of the Austrian Breast Cancer Group (ABC)].

Jakesz R, Hausmaninger H, Samonigg H, Kubista E, Haider K, Mlineritsch B, Schmid M, Tausch C, Reiner G, Renner K, Stierer M, Jatzko G, Hofbauer F, Fridrik M, Schennach W, Sevelda P, Dadak C, Haid A, Scholz R, Lenzhofer P, Steindorfer P, Berger A, Mischinger HJ.

Zentralbl Chir. 1998;123 Suppl 5:28-32. German.

PMID:
10063568
29.

Efficacy and toxicity of 2-Chlorodeoxyadenosine (Cladribine)--2 h infusion for 5 days--as first-line treatment for advanced low grade non-Hodgkin's lymphoma.

Fridrik MA, Jäger G, Kienzer HR, Hausmaninger H, Oppitz P, Krieger O, Zabernigg A, Lang A, Neubauer M, Weidinger G, Schiller L, Seewann HL, Chott A, Linkesch W.

Eur J Cancer. 1998 Sep;34(10):1560-4.

PMID:
9893628
30.

Interferon-alpha for the treatment of elderly patients with chronic myeloid leukaemia.

Hilbe W, Apfelbeck U, Fridrik M, Bernhart M, Niessner H, Abbrederis K, Michlmayr G, Pont J, Linkesch W, Hausmaninger H, Arneitz K, Baldinger C, Duba C, Eisterer W, Greil R, Konwalinka G, Niederwieser D, Gastl G, Thaler J.

Leuk Res. 1998 Oct;22(10):881-6.

PMID:
9766747
31.

Very low-dose adjuvant chemotherapy in steroid receptor negative stage I breast cancer patients. Austrian Breast Cancer Study Group.

Jakesz R, Samonigg H, Gnant M, Kubista E, Steindorfer P, Hausmaninger H, Sevelda P, Tschurtschenthaler B, Fridrik M, Stierer M, Kolb R, Steger G.

Eur J Cancer. 1998 Jan;34(1):66-70.

PMID:
9624239
32.

Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). A multicenter trial by the Austrian Working Group for Medical Tumor Therapy.

Fridrik MA, Greil R, Hausmaninger H, Krieger O, Oppitz P, Stöger M, Klocker J, Neubauer M, Helm W, Pont J, Fazeny B, Hudec M, Simonitsch I, Radaszkiewicz T.

Ann Hematol. 1997 Oct;75(4):135-40. Erratum in: Ann Hematol. 2014 Mar;93(3):539-40.

PMID:
9402845
33.

Adjunctive interferon-alpha-2c in stage IIIB/IV small-cell lung cancer: a phase III trial.

Prior C, Oroszy S, Oberaigner W, Schenk E, Kummer F, Aigner K, Hausmaninger H, Peschel C, Huber H.

Eur Respir J. 1997 Feb;10(2):392-6. Erratum in: Eur Respir J 1997 Apr;10(4):963.

34.

Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II study.

Thaler J, Hilbe W, Apfelbeck U, Linkesch W, Sill H, Seewann H, Pont J, Bernhart M, Stöger M, Niessner H, Abbrederis K, Geissler D, Hausmaninger H, Lin W, Ludwig H, Lang A, Duba C, Fluckinger T, Greil R, Grünewald K, Konwalinka G, Niederwieser D, Fridrik M.

Leuk Res. 1997 Jan;21(1):75-80.

PMID:
9029189
35.

CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.

Fridrik MA, Hausmaninger H, Linkesch W, Stöger M, Sill H, Neubauer M, Seewann HL, Klocker J, Haidinger R, Schiller L, Pont J, Raudaschl G, Falk M, Radaszkiewicz T.

J Clin Oncol. 1996 Jan;14(1):227-32.

PMID:
8558202
36.

Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer.

Hausmaninger H, Lehnert M, Steger G, Sevelda P, Tschurtschenthaler G, Hehenwarter W, Fridrik M, Samonigg H, Schiller L, Manfreda D, et al.

Eur J Cancer. 1995 Dec;31A(13-14):2169-73.

PMID:
8652237
37.

Male breast cancer: Austrian experience.

Stierer M, Rosen H, Weitensfelder W, Hausmaninger H, Teleky B, Jakesz R, Fruhwirth H, Dünser M, Beller S, Haid A, et al.

World J Surg. 1995 Sep-Oct;19(5):687-92; discussion 692-3.

PMID:
7571664
38.

Toxicity and preliminary results with a new eight-drug regimen (CEOP-IMVP-DEXA) in the treatment of aggressive lymphomas.

Fridrik MA, Hausmaninger H, Michlmayr G, Haidinger R, Seewann HL, Lehnert M.

Hematol Oncol. 1991 Jul-Oct;9(4-5):209-15.

PMID:
1743623
39.

Pirarubicin (4'-o-tetrahydropyranil-adriamycin) for treatment of advanced breast cancer. A Clinical Phase II study.

Scheithauer W, Samonigg H, Depisch D, Schüller J, Hausmaninger H, Wiegele J, Zielinsky C, Stöger H, Haider K, Preis P, et al.

Invest New Drugs. 1990 May;8(2):207-10.

PMID:
2384308
40.

Prognostic significance of tumor cell morphometry, histopathology, and clinical parameters in advanced ovarian carcinoma.

Ludescher C, Weger AR, Lindholm J, Oefner D, Hausmaninger H, Reitsamer R, Mikuz G.

Int J Gynecol Pathol. 1990;9(4):343-51.

PMID:
2246093
41.

The value of morphometry to predict chemotherapy response in advanced ovarian cancer.

Weger AR, Ludescher C, Mikuz G, Kemmler G, Reitsamer R, Hausmaninger H, Lindholm J.

Pathol Res Pract. 1989 Nov;185(5):676-9.

PMID:
2626375
42.

Vindesine-epirubicin versus vindesine-mitoxantrone in metastatic breast cancer.

Hausmaninger H, Lehnert M, Steger G, Sevelda P, Michlmayr G, Hehenwarter W, Fridrik M, Samonigg H, Schiller L, Manfreda D, et al.

Onkologie. 1989 Oct;12(5):225-9.

PMID:
2685688
43.

Steroid hormone receptors and prognosis in breast cancer.

Daxenbichler G, Forsthuber EP, Marth C, Kemmler G, Wiegele J, Margreiter R, Müller L, Hausmaninger H, Manfreda D, Dapunt O.

Breast Cancer Res Treat. 1988 Dec;12(3):267-73.

PMID:
3228589
44.

Tumour cell morphometry and response to chemotherapy in ovarian cancer.

Weger AR, Ludescher C, Mikuz G, Hausmaninger H, Lindholm J.

Lancet. 1988 Oct 29;2(8618):1020-1. No abstract available.

PMID:
2902454
45.

Treatment of herpes zoster. Recombinant alpha interferon versus acyclovir.

Duschet P, Schwarz T, Soyer P, Henk A, Hausmaninger H, Gschnait F.

Int J Dermatol. 1988 Apr;27(3):193-7.

PMID:
3286547
47.

Dose related effectiveness of alpha interferon in chronic myelogenous leukemia.

Gastl G, Aulitzky Q, Tilg H, Huber H, Hausmaninger H, Seewann HL, Coser C, Prinoth P, Huber C.

Blut. 1987 Apr;54(4):251-2. No abstract available.

PMID:
3470056
48.

Combination chemotherapy with aclarubicin in metastatic breast cancer.

Simader H, Hausmaninger H, Fereberger W, Samonigg H.

Eur J Haematol Suppl. 1987;47:71-6. No abstract available.

PMID:
3471528
49.

[Mitoxantrone in a combination regimen in advanced breast cancer].

Hausmaninger H.

Wien Med Wochenschr. 1985 Dec 31;135(23-24):594-7. German.

PMID:
4096006
50.

[Adjuvant endocrine forms of therapy in breast cancer].

Jakesz R, Hausmaninger H.

Wien Klin Wochenschr. 1984 Jun 22;96(13):492-9. German.

PMID:
6475078

Supplemental Content

Loading ...
Support Center